Version: 23 22 21 18 16 15

Item Search:

CHAPTER VIII:

REQUIRED STATUS TABLE (ITEM # ORDER)

The following table presents Version 23 of the NAACCR required status summarizing the requirements and recommendations for collection of each item by standard-setting groups. Differences from Version 22 are marked “Revised” or “New” in the “Note” column of the table and are highlighted in the body of the table. Text of previous versions is revealed by hovering over a highlighted cell.

 

NPCR	Refers to requirements and recommendations of the NPCR regarding data items that are to be collected or computed by NPCR central cancer registries. The NPCR transmit column was removed with Version 11.2. Transmit instructions are provided annually by NPCR. Note: Patient identifying data items collected are not transmitted to CDC.
CoC	Refers to requirements of CoC. CoC-accredited cancer program registries are required to collect the indicated items in the “Collect” column. Facilities should refer to the CoC STORE manual for further clarification of required fields. The CoC Transmit column has been removed with Version 21. Note: Patient identifying data items collected are not transmitted to the NCDB. The Transmit column has been removed with Version 21.
SEER	Refers to requirements of NCI’s SEER Program. Central registries are required to collect the indicated items in the “Collect” column. Facilities and central registries should refer to the SEER Program Code Manual for further clarification of required fields. The SEER Transmit column has been removed with Version 21.
CCCR	Refers to requirements of CCCR for cases submitted to the Canadian Cancer Registry. Provincial/Territorial registries should refer to the Canadian Cancer Registry Data Provider Documentation for further clarification of fields. Items indicated in the “Collect” column are required to be collected at the registry level and reported to the Canadian Cancer Registry. CCCR requirements have been added to the Required Status Table with Version 11.2. The Transmit column has been removed with Version 21.

Codes for Recommendations:

 

.	No recommendation
D	Derived
D*	Derived, when available
R	Required
R#	Required; central registries may code available data using either SEER or CoC data items and associated rules
R*	Required, when available
R^	Required, these text requirements may be met with one or several text block fields
RC	Collected by SEER from CoC-accredited hospitals
RH	Historically collected and currently transmitted
RH*	Historically collected and currently transmitted when available
RS	Required, site specific
RS*	Required, site specific; when available
S	Supplementary/recommended

Item #	Item Name	NPCR	CoC	SEER	CCCR	Source of Standard	Note
		Collect	Collect	Collect	Collect
10	Record Type	R	.	R	.	R	R	R	NAACCR
20	Patient ID Number	R	.	.	R	R	R*	R*	Reporting Registry
21	Patient System ID-Hosp	.	.	.	.	.	.	.	NAACCR
30	Registry Type	.	.	.	.	.	.	.	NAACCR
40	Registry ID	R	.	.	R	R	R	R	NAACCR
45	NPI--Registry ID	.	.	.	R*	.	.	.	CMS
50	NAACCR Record Version	R	.	R	R	R	.	.	NAACCR
60	Tumor Record Number	.	.	.	S	S	R*	R*	NAACCR
70	Addr at DX--City	R	R	R	R	.	R*	R*	CoC
80	Addr at DX--State	R	R	R	R	R	.	.	CoC
81	State at DX Geocode 1970/80/90	RH*	.	.	R	R	.	.	NAACCR
82	State at DX Geocode 2000	D	.	.	D	R	.	.	NAACCR	Revised
83	State at DX Geocode 2010	D	.	.	D	R*	.	.	NAACCR	Revised
84	State at DX Geocode 2020	D	.	.	D	.	.	.	NAACCR	Revised
89	County at DX Analysis	D	.	.	D	R	.	.	NAACCR	Revised
90	County at DX Reported	R	R	R	R	R	.	.	FIPS/SEER
94	County at DX Geocode 1970/80/90	RH*	.	.	D	R	.	.	NAACCR
95	County at DX Geocode2000	D	.	.	D	R	.	.	NAACCR
96	County at DX Geocode2010	D	.	.	D	R	.	.	NAACCR
97	County at DX Geocode2020	D	.	.	D	.	.	.	NAACCR	Revised
100	Addr at DX--Postal Code	R	R	R	R	.	R*	R*	CoC
102	Addr at DX--Country	.	R	R	R	.	.	.	NAACCR
110	Census Tract 1970/80/90	RH*	.	.	RH	RH	.	.	SEER
120	Census Cod Sys 1970/80/90	RH*	.	.	RH	RH	.	.	SEER
125	Census Tract 2020	D	.	.	D	R*	.	.	NAACCR	Revised
130	Census Tract 2000	RH	.	.	RH	RH	.	.	NAACCR
135	Census Tract 2010	R	.	.	R	R	.	.	NAACCR
145	Census Tr Poverty Indictr	D	.	.	D	R	.	.	NAACCR
150	Marital Status at DX	.	.	.	R	R	.	.	SEER
160	Race 1	R	R	R	R	R	.	.	SEER/CoC
161	Race 2	R	.	R	R	R	.	.	SEER
162	Race 3	R	.	R	R	R	.	.	SEER
163	Race 4	R	.	R	R	R	.	.	SEER
164	Race 5	R	.	R	R	R	.	.	SEER
170	Race Coding Sys--Current	.	.	R	.	.	.	.	NAACCR
180	Race Coding Sys--Original	.	.	R	.	.	.	.	NAACCR
190	Spanish/Hispanic Origin	R	R	R	R	R	.	.	SEER/CoC	Revised
191	NHIA Derived Hisp Origin	D	.	.	D	R	.	.	NAACCR
192	IHS Link	R*	.	.	R	R	.	.	NPCR	Revised
193	Race--NAPIIA(derived API)	R	.	.	.	R	.	.	NAACCR
194	IHS Purchased/Referred Care Delivery Area	D	.		D		.		NPCR
200	Computed Ethnicity	.	.	.	D	R	.	.	SEER
210	Computed Ethnicity Source	.	.	.	R	R	.	.	SEER
220	Sex	R	R	R	R	R	R	R	SEER/CoC
230	Age at Diagnosis	R	R	R	R	R	D	D	SEER/CoC
240	Date of Birth	R	R	R	R	R	R	R	SEER/CoC
250	Birthplace	RH*	.		.		.		SEER/CoC
252	Birthplace--State	R*	R	R	R	R	R	R	NAACCR
254	Birthplace--Country	R*	R	R	R	R	R	R	NAACCR
270	Census Occ Code 1970-2000	R*	.	.	.	.	.	.	Census/NPCR
272	Census Ind Code 2010 CDC	R*	.	.	.	.	.	.	Census/NPCR
280	Census Ind Code 1970-2000	R*	.	.	.	.	.	.	Census/NPCR
282	Census Occ Code 2010 CDC	R*	.	.	.	.	.	.	Census/NPCR
284	Urban Indian Health Organization (UIHO)	D	.		D		.		NPCR
285	UIHO City	D	.		D		.		NPCR
290	Occupation Source	R*	.	.	.	.	.	.	NPCR
300	Industry Source	R*	.	.	.	.	.	.	NPCR
310	Text--Usual Occupation	R*	.	.	.	.	.	.	NPCR
320	Text--Usual Industry	R*	.	.	.	.	.	.	NPCR
330	Census Occ/Ind Sys 70-00	R*	.	.	.	.	.	.	NPCR
339	RUCA 2000	D	.	.	D	R	.	.	NAACCR
341	RUCA 2010	D	.	.	D	R	.	.	NAACCR
344	Tobacco Use Smoking Status	R*	R		R*		R		NPCR	Revised
345	URIC 2000	D	.	.	D	R	.	.	NAACCR
346	URIC 2010	D	.	.	D	R	.	.	NAACCR
361	Census Block Group 2020	.	.	.	.	.	.	.	Census
362	Census Block Group 2000	.	.	.	S	.	.	.	Census
363	Census Block Group 2010	.	.	.	R	.	.	.	Census
364	Census Tr Cert 1970/80/90	RH*	.	.	RH	RH	.	.	SEER
365	Census Tr Certainty 2000	RH	.	.	RH	RH	.	.	NAACCR
366	GIS Coordinate Quality	R*	.	.	S	.	.	.	NAACCR
367	Census Tr Certainty 2010	R	.	.	R	R	.	.	NAACCR
368	Census Block Grp 1970/80/90	.	.	.	S	.	.	.	Census
369	Census Tract Certainty 2020	D	.	.	D	.	.	.	NAACCR	Revised
380	Sequence Number--Central	R	.	.	R	R	D	D	SEER
390	Date of Diagnosis	R	R	R	R	R	R	R*	SEER/CoC
400	Primary Site	R	R	R	R	R	R	R	SEER/CoC
410	Laterality	R	R	R	R	R	R	R	SEER/CoC
420	Histology (92-00) ICD-O-2	RH	RH	RH	RH	RH	RH	RH	SEER/CoC
430	Behavior (92-00) ICD-O-2	RH	RH	RH	RH	RH	RH	RH	SEER/CoC
440	Grade	RH	RH	RH	RH	RH	RH	RH	SEER/CoC
441	Grade Path Value	RH*	RH	RH	RH	RH	.	.	AJCC
442	Ambiguous Terminology DX	.	RH	RH	RH	RH	.	.	SEER
443	Date Conclusive DX	.	RH	RH	RH	RH	.	.	SEER
444	Mult Tum Rpt as One Prim	.	RH	RH	RH	RH	.	.	SEER
445	Date of Mult Tumors	.	RH	RH	RH	RH	.	.	SEER
446	Multiplicity Counter	.	RH	RH	RH	RH	.	.	SEER
449	Grade Path System	RH*	RH	RH	RH	RH	.	.	AJCC
450	Site Coding Sys--Current	R	.	R	.	.	.	.	NAACCR
460	Site Coding Sys--Original	.	.	R	.	.	R*	R*	NAACCR
470	Morph Coding Sys--Current	R	.	R	.	.	.	.	NAACCR
480	Morph Coding Sys--Originl	.	.	R	.	.	R*	R*	NAACCR
490	Diagnostic Confirmation	R	R	R	R	R	R	R	SEER/CoC
500	Type of Reporting Source	R	.	.	R	R	.	.	SEER
501	Casefinding Source	R*	.	.	.	.	.	.	NAACCR
522	Histologic Type ICD-O-3	R	R	R	R	R	R	R	SEER/CoC
523	Behavior Code ICD-O-3	R	R	R	R	R	R	R	SEER/CoC
530	EDP MDE Link Date	RS	.		.		.		NPCR
531	EDP MDE Link	RS	.		.		.		NPCR
540	Reporting Facility	R	R	R	R	.	.	.	CoC
545	NPI--Reporting Facility	R*	R	R	R*	.	.	.	CMS
550	Accession Number--Hosp	.	R	R	R	.	.	.	CoC
560	Sequence Number--Hospital	.	R	R	R	.	.	.	CoC
570	Abstracted By	.	R	R	R	.	.	.	CoC
580	Date of 1st Contact	R*	R	R	.	.	.	.	CoC	Revised
590	Date of Inpt Adm	.	.	.	.	.	.	.	NAACCR
600	Date of Inpt Disch	.	.	.	.	.	.	.	NAACCR
605	Inpatient Status	.	.	.	.	.	.	.	NAACCR
610	Class of Case	R	R	R	R	.	.	.	CoC	Revised
630	Primary Payer at DX	R*	R	R	R	R	.	.	CoC
668	RX Hosp--Surg App 2010	.	R	R	.	.	.	.	CoC
670	RX Hosp--Surg Prim Site 03-2022	.	R	R	RH	.	.	.	CoC	Revised
671	RX Hosp--Surg Prim Site 2023	.	R		R		.		CoC	New
672	RX Hosp--Scope Reg LN Sur	.	R	R	R	.	.	.	CoC
674	RX Hosp--Surg Oth Reg/Dis	.	R	R	R	.	.	.	CoC
676	RX Hosp--Reg LN Removed	.	RH	RH	.	.	.	.	CoC
682	Date Regional Lymph Node Dissection	.	R	R	RC	RC	.	.	NAACCR
690	RX Hosp--Radiation	.	.	.	RH	.	.	.	SEER
700	RX Hosp--Chemo	.	R	R	R	.	.	.	CoC
710	RX Hosp--Hormone	.	R	R	R	.	.	.	CoC
720	RX Hosp--BRM	.	R	R	R	.	.	.	CoC
730	RX Hosp--Other	.	R	R	R	.	.	.	CoC
740	RX Hosp--DX/Stg Proc	.	R	R	.	.	.	.	CoC
746	RX Hosp--Surg Site 98-02	.	RH	RH	RH	.	.	.	CoC
747	RX Hosp--Scope Reg 98-02	.	RH	RH	RH	.	.	.	CoC
748	RX Hosp--Surg Oth 98-02	.	RH	RH	RH	.	.	.	CoC
752	Tumor Size Clinical	.	.	.	R	R	R*	R*	SEER
754	Tumor Size Pathologic	.	.	.	R	R	R*	R*	SEER
756	Tumor Size Summary	R	R	R	S	S	.	.	NPCR/CoC
759	SEER Summary Stage 2000	RH	RH	RH	RH	RH	.	.	SEER
760	SEER Summary Stage 1977	RH	RH	RH	.	S	.	.	SEER
762	Derived Summary Stage 2018	.	.	.	D	R	.	.	SEER
764	Summary Stage 2018	R	.	R	R*	R*	.	.	SEER
772	EOD Primary Tumor	.	.	.	R	R	.	.	SEER
774	EOD Regional Nodes	.	.	.	R	R	.	.	SEER
776	EOD Mets	.	.	.	R	R	.	.	SEER
780	EOD--Tumor Size	.	RH	RH	RH	RH	.	.	SEER/CoC
785	Derived EOD 2018 T	.	.	.	D	R	.	.	SEER
790	EOD--Extension	.	.	.	RH	RH	.	.	SEER
795	Derived EOD 2018 M	.	.	.	D	R	.	.	SEER
800	EOD--Extension Prost Path	.	.	.	RH	RH	.	.	SEER
810	EOD--Lymph Node Involv	.	.	.	RH	RH	.	.	SEER
815	Derived EOD 2018 N	.	.	.	D	R	.	.	SEER
818	Derived EOD 2018 Stage Group	.	.	.	D	R	.	.	SEER
820	Regional Nodes Positive	R	R	R	R	R	R*	R*	SEER/CoC
830	Regional Nodes Examined	R	R	R	R	R	R*	R*	SEER/CoC
832	Date of Sentinel Lymph Node Biopsy	.	RS	RS	R*	R*	.	.	CoC
834	Sentinel Lymph Nodes Examined	.	RS	RS	RS	R*	.	.	CoC	Revised
835	Sentinel Lymph Nodes Positive	.	RS	RS	RS	R*	.	.	CoC
840	EOD--Old 13 Digit	.	.	.	RH	RH	.	.	SEER
850	EOD--Old 2 Digit	.	.	.	RH	RH	.	.	SEER
860	EOD--Old 4 Digit	.	.	.	RH	RH	.	.	SEER
870	Coding System for EOD	.	.	.	RH	RH	.	.	SEER
880	TNM Path T	.	RH	RH	RH	RH	.	.	AJCC
890	TNM Path N	.	RH	RH	RH	RH	.	.	AJCC
900	TNM Path M	.	RH	RH	RH	RH	.	.	AJCC
910	TNM Path Stage Group	.	RH	RH	RH*	RH*	.	.	AJCC
920	TNM Path Descriptor	.	RH	RH	RH	RH	.	.	CoC
930	TNM Path Staged By	.	RH	RH	RH	RH	.	.	CoC
940	TNM Clin T	.	RH	RH	RH	RH	.	.	AJCC
950	TNM Clin N	.	RH	RH	RH	RH	.	.	AJCC
960	TNM Clin M	.	RH	RH	RH	RH	.	.	AJCC
970	TNM Clin Stage Group	.	RH	RH	RH*	RH*	.	.	AJCC
980	TNM Clin Descriptor	.	RH	RH	RH	RH	.	.	CoC
990	TNM Clin Staged By	.	RH	RH	RH	RH	.	.	CoC
995	AJCC ID	D	D	R	D	RC	R*	R*	NAACCR	Revised
1001	AJCC TNM Clin T	.	R	R	RC	.	R*	R*	AJCC
1002	AJCC TNM Clin N	.	R	R	RC	.	R*	R*	AJCC
1003	AJCC TNM Clin M	.	R	R	RC	.	R*	R*	AJCC
1004	AJCC TNM Clin Stage Group	.	R	R	RC	.	R*	R*	AJCC
1011	AJCC TNM Path T	.	R	R	RC	.	R*	R*	AJCC
1012	AJCC TNM Path N	.	R	R	RC	.	R*	R*	AJCC
1013	AJCC TNM Path M	.	R	R	RC	.	R*	R*	AJCC
1014	AJCC TNM Path Stage Group	.	R	R	RC	.	R*	R*	AJCC
1021	AJCC TNM Post Therapy Path (yp) T	.	R	R	RC	.	R*	R*	AJCC
1022	AJCC TNM Post Therapy Path (yp) N	.	R	R	RC	.	R*	R*	AJCC
1023	AJCC TNM Post Therapy Path (yp) M	.	R	R	RC	.	R*	R*	AJCC
1024	AJCC TNM Post Therapy Path (yp) Stage Group	.	R	R	RC	.	R*	R*	AJCC
1031	AJCC TNM Clin T Suffix	.	R	R	RC	.	R*	R*	AJCC
1032	AJCC TNM Path T Suffix	.	R	R	RC	.	R*	R*	AJCC
1033	AJCC TNM Post Therapy Path (yp) T Suffix	.	R	R	RC	.	R*	R*	AJCC
1034	AJCC TNM Clin N Suffix	.	R	R	RC	.	R*	R*	AJCC
1035	AJCC TNM Path N Suffix	.	R	R	RC	.	R*	R*	AJCC
1036	AJCC TNM Post Therapy Path (yp) N Suffix	.	R	R	RC	.	R*	R*	AJCC
1060	TNM Edition Number	.	R	R	RH	RH	R	R	CoC
1062	AJCC TNM Post Therapy Clin (yc) T	.	R		RC		.		AJCC
1063	AJCC TNM Post Therapy Clin (yc) T Suffix	.	R		RC		.		AJCC
1064	AJCC TNM Post Therapy Clin (yc) N	.	R		RC		.		AJCC
1065	AJCC TNM Post Therapy Clin (yc) N Suffix	.	R		RC		.		AJCC
1066	AJCC TNM Post Therapy Clin (yc) M	.	R		RC		.		AJCC
1067	AJCC TNM Post Therapy Clin (yc) Stage Group	.	.		.		.		AJCC
1068	Grade Post Therapy Clin (yc)	R*	R		RS		.		NAACCR
1112	Mets at DX-Bone	.	R	R	R	R	R	R	SEER
1113	Mets at DX-Brain	.	R	R	R	R	R	R	SEER
1114	Mets at Dx-Distant LN	.	R	R	R	R	R	R	SEER
1115	Mets at DX-Liver	.	R	R	R	R	R	R	SEER
1116	Mets at DX-Lung	.	R	R	R	R	R	R	SEER
1117	Mets at DX-Other	.	R	R	R	R	R	R	SEER
1120	Pediatric Stage	.	.	.	.	.	.	.	CoC
1130	Pediatric Staging System	.	.	.	.	.	.	.	CoC
1140	Pediatric Staged By	.	.	.	.	.	.	.	CoC
1150	Tumor Marker 1	.	RH	RH	RH	RH	.	.	SEER
1160	Tumor Marker 2	.	RH	RH	RH	RH	.	.	SEER
1170	Tumor Marker 3	.	RH	RH	RH	RH	.	.	SEER
1182	Lymphovascular Invasion	R*	R	R	RS	RS	R*	R*	AJCC
1200	RX Date Surgery	R*	R	R	R	RC	.	.	CoC	Revised
1210	RX Date Radiation	R*	R	R	R	RC	.	.	CoC	Revised
1220	RX Date Chemo	R*	R	R	R	RC	.	.	CoC	Revised
1230	RX Date Hormone	R*	R	R	R	RC	.	.	CoC	Revised
1240	RX Date BRM	R*	R	R	R	RC	.	.	CoC	Revised
1250	RX Date Other	R*	R	R	R	RC	.	.	CoC	Revised
1260	Date Initial RX SEER	R#*	.	.	R	R	.	.	SEER	Revised
1270	Date 1st Crs RX CoC	R#*	R	R	.	.	.	.	CoC	Revised
1280	RX Date DX/Stg Proc	.	R	R	.	.	.	.	CoC
1285	RX Summ--Treatment Status	R#	R	R	R	R	.	.	SEER/CoC
1290	RX Summ--Surg Prim Site 03-2022	R	R	R	RH	R	.	.	SEER/CoC	Revised
1291	RX Summ--Surg Prim Site 2023	RS	R		R		.		SEER/CoC	New
1292	RX Summ--Scope Reg LN Sur	R	R	R	R	R	.	.	SEER/CoC
1294	RX Summ--Surg Oth Reg/Dis	R	R	R	R	R	.	.	SEER/CoC
1296	RX Summ--Reg LN Examined	.	RH	RH	RH	RH	.	.	SEER/CoC
1310	RX Summ--Surgical Approch	.	RH	RH	.	.	.	.	CoC
1320	RX Summ--Surgical Margins	.	R	R	R*	R*	.	.	CoC
1330	RX Summ--Reconstruct 1st	.	RH	RH	.	RH	.	.	SEER
1340	Reason for No Surgery	R	R	R	R	R	.	.	SEER/CoC
1350	RX Summ--DX/Stg Proc	.	R	R	.	.	.	.	CoC
1360	RX Summ--Radiation	RH	.	.	RH	RH	.	.	SEER
1370	RX Summ--Rad to CNS	.	.	.	RH	RH	.	.	SEER/CoC
1380	RX Summ--Surg/Rad Seq	R	R	R	R	R	.	.	SEER/CoC
1390	RX Summ--Chemo	R	R	R	R	R	.	.	SEER/CoC
1400	RX Summ--Hormone	R	R	R	R	R	.	.	SEER/CoC
1410	RX Summ--BRM	R	R	R	R	R	.	.	SEER/CoC
1420	RX Summ--Other	R	R	R	R	R	.	.	SEER/CoC
1430	Reason for No Radiation	R	R	R	R	R	.	.	CoC
1460	RX Coding System--Current	R	.	R	.	RH	.	.	NAACCR
1501	Phase I Dose per Fraction	.	R	R	R*	R*	.	.	CoC
1502	Phase I Radiation External Beam Planning Tech	.	R	R	RC	RC	.	.	CoC
1503	Phase I Number of Fractions	.	R	R	R*	R*	.	.	CoC
1504	Phase I Radiation Primary Treatment Volume	.	R	R	R*	R*	.	.	CoC
1505	Phase I Radiation to Draining Lymph Nodes	.	R	R	R*	R*	.	.	CoC
1506	Phase I Radiation Treatment Modality	R	R	R	R	R	.	.	CoC
1507	Phase I Total Dose	.	R	R	R*	R*	.	.	CoC
1510	Rad--Regional Dose: cGy	.	.	.	.	.	.	.	CoC
1511	Phase II Dose per Fraction	.	R	R	R*	R*	.	.	CoC
1512	Phase II Radiation External Beam Planning Tech	.	R	R	RC	RC	.	.	CoC
1513	Phase II Number of Fractions	.	R	R	R*	R*	.	.	CoC
1514	Phase II Radiation Primary Treatment Volume	.	R	R	R*	R*	.	.	CoC
1515	Phase II Radiation to Draining Lymph Nodes	.	R	R	R*	R*	.	.	CoC
1516	Phase II Radiation Treatment Modality	.	R	R	R	R	.	.	CoC
1517	Phase II Total Dose	.	R	R	R*	R*	.	.	CoC
1520	Rad--No of Treatment Vol	.	.	.	.	.	.	.	CoC
1521	Phase III Dose per Fraction	.	R	R	R*	R*	.	.	CoC
1522	Phase III Radiation External Beam Planning Tech	.	R	R	RC	RC	.	.	CoC
1523	Phase III Number of Fractions	.	R	R	R*	R*	.	.	CoC
1524	Phase III Radiation Primary Treatment Volume	.	R	R	R*	R*	.	.	CoC
1525	Phase III Radiation to Draining Lymph Nodes	.	R	R	R*	R*	.	.	CoC
1526	Phase III Radiation Treatment Modality	.	R	R	R	R	.	.	CoC
1527	Phase III Total Dose	.	R	R	R*	R*	.	.	CoC
1531	Radiation Treatment Discontinued Early	.	R	R	R*	R*	.	.	CoC
1532	Number of Phases of Rad Treatment to this Volume	.	R	R	R*	R*	.	.	CoC
1533	Total Dose	.	R	R	R*	R*	.	.	CoC
1540	Rad--Treatment Volume	.	.	.	.	.	.	.	CoC
1550	Rad--Location of RX	.	R	R	.	.	.	.	CoC
1570	Rad--Regional RX Modality	RH	.	.	.	.	.	.	CoC
1632	Neoadjuvant Therapy	.	.		R		.		SEER
1633	Neoadjuvant Therapy-Clinical Response	.	.		R		.		SEER
1634	Neoadjuvant Therapy-Treatment Effect	.	.		R		.		SEER
1639	RX Summ--Systemic/Sur Seq	R	R	R	R	R	.	.	CoC
1640	RX Summ--Surgery Type	.	.	.	RH	RH	.	.	SEER
1646	RX Summ--Surg Site 98-02	.	RH	RH	.	RH	.	.	SEER/CoC
1647	RX Summ--Scope Reg 98-02	.	RH	RH	RH	RH	.	.	SEER/CoC
1648	RX Summ--Surg Oth 98-02	.	RH	RH	RH	RH	.	.	SEER/CoC
1660	Subsq RX 2nd Course Date	.	.	.	.	.	.	.	CoC
1671	Subsq RX 2nd Course Surg	.	.	.	.	.	.	.	CoC
1672	Subsq RX 2nd Course Rad	.	.	.	.	.	.	.	CoC
1673	Subsq RX 2nd Course Chemo	.	.	.	.	.	.	.	CoC
1674	Subsq RX 2nd Course Horm	.	.	.	.	.	.	.	CoC
1675	Subsq RX 2nd Course BRM	.	.	.	.	.	.	.	CoC
1676	Subsq RX 2nd Course Oth	.	.	.	.	.	.	.	CoC
1677	Subsq RX 2nd--Scope LN SU	.	.	.	.	.	.	.	CoC
1678	Subsq RX 2nd--Surg Oth	.	.	.	.	.	.	.	CoC
1679	Subsq RX 2nd--Reg LN Rem	.	.	.	.	.	.	.	CoC
1680	Subsq RX 3rd Course Date	.	.	.	.	.	.	.	CoC
1691	Subsq RX 3rd Course Surg	.	.	.	.	.	.	.	CoC
1692	Subsq RX 3rd Course Rad	.	.	.	.	.	.	.	CoC
1693	Subsq RX 3rd Course Chemo	.	.	.	.	.	.	.	CoC
1694	Subsq RX 3rd Course Horm	.	.	.	.	.	.	.	CoC
1695	Subsq RX 3rd Course BRM	.	.	.	.	.	.	.	CoC
1696	Subsq RX 3rd Course Oth	.	.	.	.	.	.	.	CoC
1697	Subsq RX 3rd--Scope LN Su	.	.	.	.	.	.	.	CoC
1698	Subsq RX 3rd--Surg Oth	.	.	.	.	.	.	.	CoC
1699	Subsq RX 3rd--Reg LN Rem	.	.	.	.	.	.	.	CoC
1700	Subsq RX 4th Course Date	.	.	.	.	.	.	.	CoC
1711	Subsq RX 4th Course Surg	.	.	.	.	.	.	.	CoC
1712	Subsq RX 4th Course Rad	.	.	.	.	.	.	.	CoC
1713	Subsq RX 4th Course Chemo	.	.	.	.	.	.	.	CoC
1714	Subsq RX 4th Course Horm	.	.	.	.	.	.	.	CoC
1715	Subsq RX 4th Course BRM	.	.	.	.	.	.	.	CoC
1716	Subsq RX 4th Course Oth	.	.	.	.	.	.	.	CoC
1717	Subsq RX 4th--Scope LN Su	.	.	.	.	.	.	.	CoC
1718	Subsq RX 4th--Surg Oth	.	.	.	.	.	.	.	CoC
1719	Subsq RX 4th--Reg LN Rem	.	.	.	.	.	.	.	CoC
1741	Subsq RX--Reconstruct Del	.	.	.	.	.	.	.	CoC
1750	Date of Last Contact	R	R	R	R	R	.	.	SEER/CoC
1755	Date of Death--Canada	.	.	.	.	.	R*	R*	CCCR
1760	Vital Status	R	R	R	R	R	D	D	SEER/CoC
1762	Vital Status Recode	D	.	.	D	R	.	.	NAACCR
1770	Cancer Status	.	R	R	R*	.	.	.	CoC
1772	Date of Last Cancer (tumor) Status	.	R	R	R*	.	.	.	CoC
1775	Record Number Recode	D	.	.	D	R	.	.	NAACCR
1780	Quality of Survival	.	.	.	.	.	.	.	CoC
1782	Surv-Date Active Followup	D	.	.	D	R	.	.	NAACCR
1783	Surv-Flag Active Followup	D	.	.	D	R	.	.	NAACCR
1784	Surv-Mos Active Followup	D	.	.	D	R	.	.	NAACCR
1785	Surv-Date Presumed Alive	D	.	.	D	R	.	.	NAACCR
1786	Surv-Flag Presumed Alive	D	.	.	D	R	.	.	NAACCR
1787	Surv-Mos Presumed Alive	D	.	.	D	R	.	.	NAACCR
1788	Surv-Date DX Recode	D	.	.	D	R	.	.	NAACCR
1790	Follow-Up Source	R*	R	.	.	.	.	.	CoC
1791	Follow-up Source Central	R	.	.	.	.	.	.	NAACCR
1800	Next Follow-Up Source	.	R	.	.	.	.	.	CoC
1810	Addr Current--City	.	.	.	R	.	.	.	SEER
1820	Addr Current--State	.	.	.	R	.	.	.	SEER
1830	Addr Current--Postal Code	.	.	.	R	.	.	.	SEER
1832	Addr Current--Country	.	.	.	R	.	.	.	NAACCR
1840	County--Current	.	.	.	.	.	.	.	NAACCR
1842	Follow-Up Contact--City	.	.	.	.	.	.	.	SEER
1844	Follow-Up Contact--State	.	.	.	.	.	.	.	SEER
1846	Follow-Up Contact--Postal	.	.	.	.	.	.	.	SEER
1847	FollowUp Contact--Country	.	.	.	.	.	.	.	NAACCR
1850	Unusual Follow-Up Method	.	.	.	.	.	.	.	NAACCR
1854	No Patient Contact Flag	.	.		R		.		NAACCR	New
1856	Reporting Facility Restriction Flag	.	.		R		.		NAACCR	New
1860	Recurrence Date--1st	.	R	R	RC	.	.	.	CoC
1880	Recurrence Type--1st	.	R	R	RC	.	.	.	CoC
1910	Cause of Death	R	.	.	R	R	R*	R*	SEER
1914	SEER Cause Specific COD	D	.	.	D	R	.	.	SEER
1915	SEER Other COD	D	.	.	D	R	.	.	SEER
1920	ICD Revision Number	R	.	.	R	R	.	.	SEER
1930	Autopsy	.	.	.	.	.	.	.	NAACCR
1940	Place of Death	RH	.		.		R*		NPCR
1942	Place of Death--State	R	.	.	R	R	D	D	NAACCR
1944	Place of Death--Country	R*	.	.	R	R	D	D	NAACCR
1960	Site (73-91) ICD-O-1	.	.	.	RH	RH	.	.	SEER
1971	Histology (73-91) ICD-O-1	.	.	.	RH	RH	.	.	SEER
1972	Behavior (73-91) ICD-O-1	.	.	.	RH	RH	.	.	SEER
1973	Grade (73-91) ICD-O-1	.	.	.	RH	RH	.	.	SEER
1981	Over-ride SS/NodesPos	.	.	.	RH	RH	.	.	NAACCR
1982	Over-ride SS/TNM-N	.	.	.	RH	RH	.	.	NAACCR
1983	Over-ride SS/TNM-M	.	.	.	RH	RH	.	.	NAACCR
1985	Over-ride Acsn/Class/Seq	.	.	R	.	.	.	.	NAACCR
1986	Over-ride HospSeq/DxConf	.	.	R	.	.	.	.	NAACCR
1987	Over-ride CoC-Site/Type	.	.	R	.	.	.	.	NAACCR
1988	Over-ride HospSeq/Site	.	.	R	.	.	.	.	NAACCR
1989	Over-ride Site/TNM-StgGrp	.	.	R	R	R	.	.	NAACCR
1990	Over-ride Age/Site/Morph	R	.	R	R	R	.	.	SEER
1992	Over-ride TNM Stage	.	.	.	.	.	.	.	NAACCR
1993	Over-ride TNM Tis	.	.	.	R	R	.	.	NAACCR
1994	Over-ride TNM 3	.	.	.	.	.	.	.	NAACCR
2000	Over-ride SeqNo/DxConf	R	.	.	R	R	.	.	SEER
2010	Over-ride Site/Lat/SeqNo	R	.	.	R	R	.	.	SEER
2020	Over-ride Surg/DxConf	R	.	R	R	R	.	.	SEER
2030	Over-ride Site/Type	R	.	R	R	R	.	.	SEER
2040	Over-ride Histology	R	.	R	R	R	.	.	SEER
2050	Over-ride Report Source	R	.	.	R	R	.	.	SEER
2060	Over-ride Ill-define Site	R	.	.	R	R	.	.	SEER
2070	Over-ride Leuk, Lymphoma	R	.	R	R	R	.	.	SEER
2071	Over-ride Site/Behavior	R	.	R	R	R	.	.	SEER
2072	Over-ride Site/EOD/DX Dt	.	.	.	R	R	.	.	SEER
2073	Over-ride Site/Lat/EOD	.	.	.	R	R	.	.	SEER
2074	Over-ride Site/Lat/Morph	R	.	R	R	R	.	.	SEER
2078	Over-ride Name/Sex	R	.	.	R	R	.	.	NAACCR
2081	CRC CHECKSUM	.	.	.	S	S	.	.	NAACCR
2085	Date Case Initiated	.	.	.	.	.	.	.	NAACCR
2090	Date Case Completed	.	.	.	.	.	.	.	NAACCR
2092	Date Case Completed--CoC	.	D	D	.	.	.	.	CoC
2100	Date Case Last Changed	.	D	D	.	.	.	.	NAACCR
2110	Date Case Report Exported	R	.	.	R	.	.	.	NPCR	Revised
2111	Date Case Report Received	R	.	.	R	.	.	.	NPCR	Revised
2112	Date Case Report Loaded	R	.	.	R	.	.	.	NPCR	Revised
2113	Date Tumor Record Availbl	R	.	.	D	.	.	.	NPCR	Revised
2116	ICD-O-3 Conversion Flag	R	.	.	R	R	.	.	SEER
2117	Schema ID Version Current	D	D		D		R*		SEER
2118	Schema ID Version Original	D	D		D		R*		SEER
2140	CoC Coding Sys--Current	.	.	R	.	.	.	.	CoC
2150	CoC Coding Sys--Original	.	.	R	.	.	.	.	CoC
2152	CoC Accredited Flag	R	.	.	R	R	.	.	NPCR
2155	RQRS NCDB Submission Flag	.	.	R	.	.	.	.	CoC
2156	AJCC API Version Current	.	D		D*		R*		AJCC
2157	AJCC API Version Original	.	D		D*		R*		AJCC
2158	AJCC Cancer Surveillance DLL Version Current	D	D		.		R*		AJCC	Revised
2159	AJCC Cancer Surveillance DLL Version Original	D	D		.		R*		AJCC	Revised
2170	Vendor Name	.	R	R	.	.	.	.	NAACCR
2200	Diagnostic Proc 73-87	.	.	.	.	RH	.	.	SEER
2230	Name--Last	R	.	.	R	.	R	R	SEER
2232	Name--Birth Surname	R	.		R		R*		NAACCR
2240	Name--First	R	.	.	R	.	R*	R*	SEER
2250	Name--Middle	R	.	.	R	.	R*	R*	SEER
2260	Name--Prefix	.	.	.	.	.	.	.	NAACCR
2270	Name--Suffix	.	.	.	R	.	.	.	NAACCR
2280	Name--Alias	R	.	.	R	.	.	.	NAACCR
2290	Name--Spouse/Parent	.	.	.	.	.	.	.	NAACCR
2300	Medical Record Number	R	.	.	R	.	.	.	NAACCR
2310	Military Record No Suffix	.	.	.	.	.	.	.	CoC
2315	Medicare Beneficiary Identifier	R*	.		.		.		NAACCR
2320	Social Security Number	R	.	.	R	.	.	.	SEER
2330	Addr at DX--No & Street	R	.	.	R	.	.	.	SEER
2335	Addr at DX--Supplementl	R	.	.	R	.	.	.	SEER
2350	Addr Current--No & Street	.	.	.	R	.	.	.	SEER
2352	Latitude	R*	.	.	S	.	.	.	NAACCR
2354	Longitude	R*	.	.	S	.	.	.	NAACCR
2355	Addr Current--Supplementl	.	.	.	R*	.	.	.	SEER
2360	Telephone	.	.	.	R	.	.	.	SEER
2380	DC State File Number	R	.	.	R*	.	.	.	State
2390	Name--Maiden	.	.		.		R*		NAACCR
2392	Follow-Up Contact--No&St	.	.	.	.	.	.	.	SEER
2393	Follow-Up Contact--Suppl	.	.	.	.	.	.	.	SEER
2394	Follow-Up Contact--Name	.	.	.	.	.	.	.	SEER
2410	Institution Referred From	.	.	.	.	.	.	.	CoC
2415	NPI--Inst Referred From	.	R	.	.	.	.	.	CMS
2420	Institution Referred To	.	.	.	.	.	.	.	CoC
2425	NPI--Inst Referred To	.	R	.	.	.	.	.	CMS
2440	Following Registry	.	.	.	RH	.	.	.	CoC
2445	NPI--Following Registry	.	.	.	RH*	.	.	.	CMS
2460	Physician--Managing	.	.	.	.	.	.	.	NAACCR
2465	NPI--Physician--Managing	.	.	.	.	.	.	.	CMS
2470	Physician--Follow-Up	.	.	.	R	.	.	.	CoC
2475	NPI--Physician--Follow-Up	.	.	.	R*	.	.	.	CMS
2480	Physician--Primary Surg	.	.	.	.	.	.	.	CoC
2485	NPI--Physician--Primary Surg	.	R	R	.	.	.	.	CMS
2490	Physician 3	.	.	.	.	.	.	.	CoC
2495	NPI--Physician 3	.	R	R	.	.	.	.	CMS
2500	Physician 4	.	.	.	.	.	.	.	CoC
2505	NPI--Physician 4	.	R	R	.	.	.	.	CMS
2508	EHR Reporting	.	.	.	.	.	.	.	NAACCR
2520	Text--DX Proc--PE	R^	.	.	R	.	.	.	NPCR
2530	Text--DX Proc--X-ray/Scan	R^	.	.	R	.	.	.	NPCR
2540	Text--DX Proc--Scopes	R^	.	.	R	.	.	.	NPCR
2550	Text--DX Proc--Lab Tests	R^	.	.	R	.	.	.	NPCR
2560	Text--DX Proc--Op	R^	.	.	R	.	.	.	NPCR
2570	Text--DX Proc--Path	R^	.	.	R	.	.	.	NPCR
2580	Text--Primary Site Title	R^	.	.	R	.	.	.	NPCR
2590	Text--Histology Title	R^	.	.	R	.	.	.	NPCR
2600	Text--Staging	R^	.	.	R	.	.	.	NPCR
2610	RX Text--Surgery	R^	.	.	R	.	.	.	NPCR
2620	RX Text--Radiation (Beam)	R^	.	.	R	.	.	.	NPCR
2630	RX Text--Radiation Other	R^	.	.	R	.	.	.	NPCR
2640	RX Text--Chemo	R^	.	.	R	.	.	.	NPCR
2650	RX Text--Hormone	R^	.	.	R	.	.	.	NPCR
2660	RX Text--BRM	R^	.	.	R	.	.	.	NPCR
2670	RX Text--Other	R^	.	.	R	.	.	.	NPCR
2680	Text--Remarks	.	.	.	R	.	.	.	NPCR
2690	Text--Place of Diagnosis	.	.	.	.	.	.	.	NPCR
2800	CS Tumor Size	RH*	RH	RH	RH*	RH*	RH*	RH*	AJCC
2810	CS Extension	RH*	RH	RH	RH*	RH*	RH*	RH*	AJCC
2820	CS Tumor Size/Ext Eval	RH*	RH	RH	RH*	RH*	RH*	RH*	AJCC
2830	CS Lymph Nodes	RH*	RH	RH	RH*	RH*	RH*	RH*	AJCC
2840	CS Lymph Nodes Eval	RH*	RH	RH	RH*	RH*	RH*	RH*	AJCC
2850	CS Mets at DX	RH*	RH	RH	RH*	RH*	RH*	RH*	AJCC
2851	CS Mets at Dx-Bone	.	RH	RH	RH	RH	RH*	RH*	AJCC
2852	CS Mets at Dx-Brain	.	RH	RH	RH	RH	RH*	RH*	AJCC
2853	CS Mets at Dx-Liver	.	RH	RH	RH	RH	RH*	RH*	AJCC
2854	CS Mets at Dx-Lung	.	RH	RH	RH	RH	RH*	RH*	AJCC
2860	CS Mets Eval	RH*	RH	RH	RH*	RH*	RH*	RH*	AJCC
2861	CS Site-Specific Factor 7	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2862	CS Site-Specific Factor 8	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2863	CS Site-Specific Factor 9	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2864	CS Site-Specific Factor10	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2865	CS Site-Specific Factor11	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2866	CS Site-Specific Factor12	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2867	CS Site-Specific Factor13	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2868	CS Site-Specific Factor14	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2869	CS Site-Specific Factor15	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2870	CS Site-Specific Factor16	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2871	CS Site-Specific Factor17	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2872	CS Site-Specific Factor18	.	RH	RH	RH	RH	RH*	RH*	AJCC
2873	CS Site-Specific Factor19	.	RH	RH	RH	RH	RH*	RH*	AJCC
2874	CS Site-Specific Factor20	.	RH	RH	RH	RH	RH*	RH*	AJCC
2875	CS Site-Specific Factor21	.	RH	RH	RH	RH	RH*	RH*	AJCC
2876	CS Site-Specific Factor22	.	RH	RH	RH	RH	RH*	RH*	AJCC
2877	CS Site-Specific Factor23	.	RH	RH	RH	RH	RH*	RH*	AJCC
2878	CS Site-Specific Factor24	.	RH	RH	RH	RH	RH*	RH*	AJCC
2879	CS Site-Specific Factor25	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2880	CS Site-Specific Factor 1	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2890	CS Site-Specific Factor 2	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2900	CS Site-Specific Factor 3	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2910	CS Site-Specific Factor 4	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2920	CS Site-Specific Factor 5	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2930	CS Site-Specific Factor 6	RH*	RH	RH	RH	RH	RH*	RH*	AJCC
2935	CS Version Input Original	R*	RH	RH	RH*	RH*	RH*	RH*	AJCC
2936	CS Version Derived	RH*	DH	DH	D*	DH*	DH	DH	AJCC
2937	CS Version Input Current	R*	RH	RH	RH*	RH*	RH*	RH*	AJCC
2940	Derived AJCC-6 T	.	DH	DH	DH	RH	DH	DH	AJCC
2950	Derived AJCC-6 T Descript	.	DH	DH	DH	RH	DH	DH	AJCC
2960	Derived AJCC-6 N	.	DH	DH	DH	RH	DH	DH	AJCC
2970	Derived AJCC-6 N Descript	.	DH	DH	DH	RH	DH	DH	AJCC
2980	Derived AJCC-6 M	.	DH	DH	DH	RH	DH	DH	AJCC
2990	Derived AJCC-6 M Descript	.	DH	DH	DH	RH	DH	DH	AJCC
3000	Derived AJCC-6 Stage Grp	.	DH	DH	DH	RH	DH	DH	AJCC
3010	Derived SS1977	.	DH	DH	D*	S	DH	DH	AJCC
3020	Derived SS2000	RH*	DH	DH	DH	R+	DH	DH	AJCC	Revised
3030	Derived AJCC--Flag	.	DH	DH	DH	RH	.	.	AJCC
3040	Derived SS1977--Flag	.	DH	DH	D*	S	.	.	AJCC
3050	Derived SS2000--Flag	RH*	DH	DH	D*	S	.	.	AJCC
3100	Archive FIN	.	R	R	.	.	.	.	CoC
3105	NPI--Archive FIN	.	R	R	.	.	.	.	CMS
3110	Comorbid/Complication 1	.	RH	RH	.	.	.	.	CoC
3120	Comorbid/Complication 2	.	RH	RH	.	.	.	.	CoC
3130	Comorbid/Complication 3	.	RH	RH	.	.	.	.	CoC
3140	Comorbid/Complication 4	.	RH	RH	.	.	.	.	CoC
3150	Comorbid/Complication 5	.	RH	RH	.	.	.	.	CoC
3160	Comorbid/Complication 6	.	RH	RH	.	.	.	.	CoC
3161	Comorbid/Complication 7	.	RH	RH	.	.	.	.	CoC
3162	Comorbid/Complication 8	.	RH	RH	.	.	.	.	CoC
3163	Comorbid/Complication 9	.	RH	RH	.	.	.	.	CoC
3164	Comorbid/Complication 10	.	RH	RH	.	.	.	.	CoC
3165	ICD Revision Comorbid	.	.	.	.	.	.	.	CoC
3170	RX Date Mst Defn Srg	R*	R	R	RC	RC	.	.	CoC	Revised
3180	RX Date Surg Disch	.	R	R	.	.	.	.	CoC
3190	Readm Same Hosp 30 Days	.	R	R	.	.	.	.	CoC
3200	Rad--Boost RX Modality	.	.	.	.	.	.	.	CoC
3210	Rad--Boost Dose cGy	.	.	.	.	.	.	.	CoC
3220	RX Date Rad Ended	.	R	R	.	.	.	.	CoC
3230	RX Date Systemic	.	R	R	RC	RC	.	.	CoC
3250	RX Summ--Transplnt/Endocr	R	R	R	R	R	.	.	CoC
3270	RX Summ--Palliative Proc	.	R	R	.	.	.	.	CoC
3280	RX Hosp--Palliative Proc	.	R	R	.	.	.	.	CoC
3300	RuralUrban Continuum 1993	D	.	.	D	.	.	.	NAACCR	Revised
3310	RuralUrban Continuum 2003	D	.	.	D	.	.	.	NAACCR	Revised
3312	RuralUrban Continuum 2013	D	.	.	D	R	.	.	NAACCR
3400	Derived AJCC-7 T	RH*	DH	DH	DH	RH	DH	DH	AJCC
3402	Derived AJCC-7 T Descript	RH*	DH	DH	DH	RH	DH	DH	AJCC
3410	Derived AJCC-7 N	RH*	DH	DH	DH	RH	DH	DH	AJCC
3412	Derived AJCC-7 N Descript	RH*	DH	DH	DH	RH	DH	DH	AJCC
3420	Derived AJCC-7 M	RH*	DH	DH	DH	RH	DH	DH	AJCC
3422	Derived AJCC-7 M Descript	RH*	DH	DH	DH	RH	DH	DH	AJCC
3430	Derived AJCC-7 Stage Grp	RH*	DH	DH	DH	RH	DH	DH	AJCC
3440	Derived PreRx-7 T	.	.	.	.	.	.	.	AJCC
3442	Derived PreRx-7 T Descrip	.	.	.	.	.	.	.	AJCC
3450	Derived PreRx-7 N	.	.	.	.	.	.	.	AJCC
3452	Derived PreRx-7 N Descrip	.	.	.	.	.	.	.	AJCC
3460	Derived PreRx-7 M	.	.	.	.	.	.	.	AJCC
3462	Derived PreRx-7 M Descrip	.	.	.	.	.	.	.	AJCC
3470	Derived PreRx-7 Stage Grp	.	.	.	.	.	.	.	AJCC
3480	Derived PostRx-7 T	.	.	.	.	.	.	.	AJCC
3482	Derived PostRx-7 N	.	.	.	.	.	.	.	AJCC
3490	Derived PostRx-7 M	.	.	.	.	.	.	.	AJCC
3492	Derived PostRx-7 Stge Grp	.	.	.	.	.	.	.	AJCC
3600	Derived Neoadjuv Rx Flag	.	.	.	.	.	.	.	AJCC
3605	Derived SEER Path Stg Grp	.	.	.	DH	RH	.	.	SEER
3610	Derived SEER Clin Stg Grp	.	.	.	DH	RH	.	.	SEER
3614	Derived SEER Cmb Stg Grp	.	.	.	DH	RH	.	.	SEER
3616	Derived SEER Combined T	.	.	.	DH	RH	.	.	SEER
3618	Derived SEER Combined N	.	.	.	DH	RH	.	.	SEER
3620	Derived SEER Combined M	.	.	.	DH	RH	.	.	SEER
3622	Derived SEER Cmb T Src	.	.	.	DH	RH	.	.	SEER
3624	Derived SEER Cmb N Src	.	.	.	DH	RH	.	.	SEER
3626	Derived SEER Cmb M Src	.	.	.	DH	RH	.	.	SEER
3645	NPCR Derived AJCC 8 TNM Clin Stg Grp	.	.	.	.	.	R*	R*	NPCR
3646	NPCR Derived AJCC 8 TNM Path Stg Grp	.	.	.	.	.	R*	R*	NPCR
3647	NPCR Derived AJCC 8 TNM Post Therapy Stg Grp	.	.	.	.	.	R*	R*	NPCR
3650	NPCR Derived Clin Stg Grp	.	.	.	.	.	.	.	NPCR
3655	NPCR Derived Path Stg Grp	.	.	.	.	.	.	.	NPCR
3700	SEER Site-Specific Fact 1	.	.	.	R	R	.	.	SEER
3702	SEER Site-Specific Fact 2	.	.	.	.	.	.	.	SEER
3704	SEER Site-Specific Fact 3	.	.	.	.	.	.	.	SEER
3706	SEER Site-Specific Fact 4	.	.	.	.	.	.	.	SEER
3708	SEER Site-Specific Fact 5	.	.	.	.	.	.	.	SEER
3710	SEER Site-Specific Fact 6	.	.	.	.	.	.	.	SEER
3750	Over-ride CS 1	.	RH	RH	.	.	.	.	AJCC
3751	Over-ride CS 2	.	RH	RH	.	.	.	.	AJCC
3752	Over-ride CS 3	.	RH	RH	.	.	.	.	AJCC
3753	Over-ride CS 4	.	RH	RH	.	.	.	.	AJCC
3754	Over-ride CS 5	.	RH	RH	.	.	.	.	AJCC
3755	Over-ride CS 6	.	RH	RH	.	.	.	.	AJCC
3756	Over-ride CS 7	.	RH	RH	.	.	.	.	AJCC
3757	Over-ride CS 8	.	RH	RH	.	.	.	.	AJCC
3758	Over-ride CS 9	.	RH	RH	.	.	.	.	AJCC
3759	Over-ride CS 10	.	RH	RH	.	.	.	.	AJCC
3760	Over-ride CS 11	.	RH	RH	.	.	.	.	AJCC
3761	Over-ride CS 12	.	RH	RH	.	.	.	.	AJCC
3762	Over-ride CS 13	.	RH	RH	.	.	.	.	AJCC
3763	Over-ride CS 14	.	RH	RH	.	.	.	.	AJCC
3764	Over-ride CS 15	.	RH	RH	.	.	.	.	AJCC
3765	Over-ride CS 16	.	RH	RH	.	.	.	.	AJCC
3766	Over-ride CS 17	.	RH	RH	.	.	.	.	AJCC
3767	Over-ride CS 18	.	RH	RH	.	.	.	.	AJCC
3768	Over-ride CS 19	.	RH	RH	.	.	.	.	AJCC
3769	Over-ride CS 20	RH	RH	RH	RH	RH	.	.	AJCC/NPCR
3780	Secondary Diagnosis 1	.	R	R	R*	.	.	.	CoC	Revised
3782	Secondary Diagnosis 2	.	R	R	R*	.	.	.	CoC	Revised
3784	Secondary Diagnosis 3	.	R	R	R*	.	.	.	CoC	Revised
3786	Secondary Diagnosis 4	.	R	R	R*	.	.	.	CoC	Revised
3788	Secondary Diagnosis 5	.	R	R	R*	.	.	.	CoC	Revised
3790	Secondary Diagnosis 6	.	R	R	R*	.	.	.	CoC	Revised
3792	Secondary Diagnosis 7	.	R	R	R*	.	.	.	CoC	Revised
3794	Secondary Diagnosis 8	.	R	R	R*	.	.	.	CoC	Revised
3796	Secondary Diagnosis 9	.	R	R	R*	.	.	.	CoC	Revised
3798	Secondary Diagnosis 10	.	R	R	R*	.	.	.	CoC	Revised
3800	Schema ID	D	D	R	D	R	D	R	NAACCR
3801	Chromosome 1p: Loss of Heterozygosity (LOH)	.	RS	RS	RS	RS	.	.	NAACCR
3802	Chromosome 19q: Loss of Heterozygosity (LOH)	.	RS	RS	RS	RS	.	.	NAACCR
3803	Adenoid Cystic Basaloid Pattern	.	RS	RS	RS	RS	.	.	NAACCR
3804	Adenopathy	.	RS	RS	RS	RS	RS*	RS	NAACCR
3805	AFP Post-Orchiectomy Lab Value	.	RS	RS	RC	RC	.	.	NAACCR
3806	AFP Post-Orchiectomy Range	.	RS	RS	RS	RS	.	.	NAACCR
3807	AFP Pre-Orchiectomy Lab Value	.	RS	RS	RC	RC	.	.	NAACCR
3808	AFP Pre-Orchiectomy Range	.	RS	.	RS	.	.	.	NAACCR
3809	AFP Pretreatment Interpretation	.	RS	RS	RC	RC	RS*	RS	NAACCR
3810	AFP Pretreatment Lab Value	.	RS	RS	RC	RC	.	.	NAACCR
3811	Anemia	.	RS	RS	RS	RS	RS*	RS	NAACCR
3812	B symptoms	.	RS	RS	RS	RS	RS*	RS	NAACCR
3813	Bilirubin Pretreatment Total Lab Value	.	RS	RS	RC	RC	.	.	NAACCR
3814	Bilirubin Pretreatment Unit of Measure	.	RS	RS	RC	RC	.	.	NAACCR
3815	Bone Invasion	.	RS	RS	RS	RS	.	.	NAACCR
3816	Brain Molecular Markers	RS	.	.	RS	RS	.	.	NAACCR
3817	Breslow Tumor Thickness	RS	RS	RS	RS	RS	RS*	RS	NAACCR
3818	CA-125 Pretreatment Interpretation	.	RS	RS	RS	RS	RS*	RS	NAACCR
3819	CEA Pretreatment Interpretation	.	RS	RS	RS	RS	RS*	RS	NAACCR
3820	CEA Pretreatment Lab Value	.	RS	RS	RS	RS	.	.	NAACCR
3821	Chromosome 3 Status	.	RS	RS	RC	RC	.	.	NAACCR
3822	Chromosome 8q Status	.	RS	RS	RC	RC	.	.	NAACCR
3823	Circumferential Resection Margin (CRM)	.	RS	RS	RS	RS	RS*	RS	NAACCR
3824	Creatinine Pretreatment Lab Value	.	RS	RS	RC	RC	.	.	NAACCR
3825	Creatinine Pretreatment Unit of Measure	.	RS	RS	RC	RC	.	.	NAACCR
3826	Estrogen Receptor Percent Positive or Range	.	RS	RS	RC	RC	.	.	NAACCR
3827	Estrogen Receptor Summary	RS	RS	RS	RS	RS	RS*	RS	NAACCR
3828	Estrogen Receptor Total Allred Score	.	RS	RS	.	RC	.	.	NAACCR	Revised
3829	Esophagus and EGJ Tumor Epicenter	RS	RS	RS	RS	RS	RS*	RS	NAACCR
3830	Extranodal Extension Clin (non-Head and Neck)	.	RS	RS	RC	RC	.	.	NAACCR
3831	Extranodal Extension Head and Neck Clinical	.	RS	RS	RC	RC	.	.	NAACCR
3832	Extranodal Extension Head and Neck Pathological	.	RS	RS	RS	RS	RS*	RS	NAACCR
3833	Extranodal Extension Path (non-Head and Neck)	.	RS	RS	RC	RC	.	.	NAACCR
3834	Extravascular Matrix Patterns	.	RS	RS	RC	RC	.	.	NAACCR
3835	Fibrosis Score	RS	RS	RS	RS	RC	.	.	NAACCR	Revised
3836	FIGO Stage	.	RS	RS	RS	RS	.	.	NAACCR
3837	Gestational Trophoblastic Prognostic Scoring Index	.	RS	RS	RS	RS	RS*	RS	NAACCR
3838	Gleason Patterns Clinical	RS	RS	RS	RS	RS	RS*	RS	NAACCR
3839	Gleason Patterns Pathological	RS	RS	RS	RS	RS	RS*	RS*	NAACCR
3840	Gleason Score Clinical	RS	RS	RS	RS	RC	RS*	RS	NAACCR	Revised
3841	Gleason Score Pathological	RS	RS	RS	RS	RC	RS*	RS	NAACCR	Revised
3842	Gleason Tertiary Pattern	RS*	RS	RS	RS*	RC	RS*	RS	NAACCR	Revised
3843	Grade Clinical	R	R	R	R	R	R	R	NAACCR
3844	Grade Pathological	R	R	R	R	R	R	R	NAACCR
3845	Grade Post Therapy Path (yp)	R*	R	R	RS	RS	R	R	NAACCR
3846	hCG Post-Orchiectomy Lab Value	.	RS	RS	RC	RC	.	.	NAACCR
3847	hCG Post-Orchiectomy Range	.	RS	RS	RS	RS	.	.	NAACCR
3848	hCG Pre-Orchiectomy Lab Value	.	RS	RS	RC	RC	.	.	NAACCR
3849	hCG Pre-Orchiectomy Range	.	RS	RS	RS	RS	.	.	NAACCR
3850	HER2 IHC Summary	.	.	.	.	RC	RH*	RS	NAACCR
3851	HER2 ISH Dual Probe Copy Number	.	.	.	.	RC	.	.	NAACCR
3852	HER2 ISH Dual Probe Ratio	.	.	.	.	RC	.	.	NAACCR
3853	HER2 ISH Single Probe Copy Number	.	.	.	.	RC	.	.	NAACCR
3854	HER2 ISH Summary	.	.	.	.	RC	RH*	RS	NAACCR
3855	HER2 Overall Summary	RS	RS	RS	RS	RS	RS*	RS	NAACCR
3856	Heritable Trait	.	RS	RS	RS	RS	RS*	RS	NAACCR
3857	High Risk Cytogenetics	.	RS	RS	RS	RS	RS*	RS	NAACCR
3858	High Risk Histologic Features	.	RS	RS	RS	RS	.	.	NAACCR
3859	HIV Status	.	.	RS	RS	RS	.	.	NAACCR
3860	International Normalized Ratio Prothrombin Time	.	RS	RS	RC	RC	.	.	NAACCR
3861	Ipsilateral Adrenal Gland Involvement	.	RS	RS	RS	RS	.	.	NAACCR
3862	JAK2	.	RS	RS	RS	RS	.	.	NAACCR
3863	Ki-67	.	RS	RS	RC	RC	.	.	NAACCR
3864	Invasion Beyond Capsule	.	RS	RS	RS	RS	.	.	NAACCR
3865	KIT Gene Immunohistochemistry	.	RS	RS	RC	RC	RS*	RS	NAACCR
3866	KRAS	.	RS	RS	RS	RS	.	.	NAACCR
3867	LDH Post-Orchiectomy Range	.	RS	RS	RS	RS	.	.	NAACCR
3868	LDH Pre-Orchiectomy Range	.	RS	RS	RS	RS	.	.	NAACCR
3869	LDH Level	.	RS	RS	RS	RS	RS*	RS	NAACCR
3870	LDH Upper Limits of Normal	.	RS	RS	RC	RC	.	.	NAACCR
3871	LN Assessment Method Femoral-Inguinal	.	RS	RS	RC	RC	.	.	NAACCR
3872	LN Assessment Method Para-Aortic	.	RS	RS	RC	RC	.	.	NAACCR
3873	LN Assessment Method Pelvic	.	RS	RS	RC	RC	.	.	NAACCR
3874	LN Distant Assessment Method	.	RS	RS	RC	RC	.	.	NAACCR
3875	LN Distant: Mediastinal, Scalene	.	RS	RS	RC	RC	.	.	NAACCR
3876	LN Head and Neck Levels I-III	.	RS	RS	RS	RS	.	.	NAACCR
3877	LN Head and Neck Levels IV-V	.	RS	RS	RS	RS	.	.	NAACCR
3878	LN Head and Neck Levels VI-VII	.	RS	RS	RS	RS	.	.	NAACCR
3879	LN Head and Neck Other	.	RS	RS	RS	RS	.	.	NAACCR
3880	LN Isolated Tumor Cells (ITC)	.	RS	RS	RS	RS	.	.	NAACCR
3881	LN Laterality	.	RS	RS	RS	RS	.	.	NAACCR
3882	LN Positive Axillary Level I-II	.	RS	RS	RS	RS	.	.	NAACCR
3883	LN Size	.	RS	RS	RS	RS	RS*	RS	NAACCR
3884	LN Status Femoral-Inguinal, Para-Aortic, Pelvic	.	.		.		.		NAACCR	Revised
3885	Lymphocytosis	.	RS	RS	RS	RS	RS*	RS	NAACCR
3886	Major Vein Involvement	.	RS	RS	RS	RS	.	.	NAACCR
3887	Measured Basal Diameter	.	RS	RS	RS	RS	.	.	NAACCR
3888	Measured Thickness	.	RS	RS	RS	RS	.	.	NAACCR
3889	Methylation of O6-Methylguanine-Methyltransferase	.	RS	RS	RS	RS	.	.	NAACCR
3890	Microsatellite Instability (MSI)	RS*	RS	RS	RS	RS	RS*	RS	NAACCR
3891	Microvascular Density	.	RS	RS	RC	RC	.	.	NAACCR
3892	Mitotic Count Uveal Melanoma	.	RS	RS	RC	RC	.	.	NAACCR
3893	Mitotic Rate Melanoma	.	RS	RS	RS	RS	RS*	RS	NAACCR
3894	Multigene Signature Method	.	RS	RS	RS	RS	.	.	NAACCR
3895	Multigene Signature Results	.	RS	RS	RS	RS	.	.	NAACCR
3896	NCCN International Prognostic Index (IPI)	.	RS	RS	RS	RS	.	.	NAACCR
3897	Number of Cores Examined	.	RS	RS	RS	RS	RS*	RS	NAACCR
3898	Number of Cores Positive	.	RS	RS	RS	RS	RS*	RS	NAACCR
3899	Number of Examined Para-Aortic Nodes	.	RS	RS	RC	RC	.	.	NAACCR
3900	Number of Examined Pelvic Nodes	.	RS	RS	RC	RC	.	.	NAACCR
3901	Number of Positive Para-Aortic Nodes	.	RS	RS	RC	RC	.	.	NAACCR
3902	Number of Positive Pelvic Nodes	.	RS	RS	RC	RC	.	.	NAACCR
3903	Oncotype Dx Recurrence Score-DCIS	.	RS	RS	RC	RC	.	.	NAACCR
3904	Oncotype Dx Recurrence Score-Invasive	.	RS	RS	RS	RS	RS*	RS	NAACCR
3905	Oncotype Dx Risk Level-DCIS	.	RS	RS	RC	RC	.	.	NAACCR
3906	Oncotype Dx Risk Level-Invasive	.	RS	RS	RC	RC	.	.	NAACCR
3907	Organomegaly	.	RS	RS	RS	RS	RS*	RS	NAACCR
3908	Percent Necrosis Post Neoadjuvant	.	RS	RS	RC	RC	RS*	RS	NAACCR
3909	Perineural Invasion	.	RS	RS	RS	RS	.	.	NAACCR
3910	Peripheral Blood Involvement	.	RS	RS	RS	RS	RS*	RS	NAACCR
3911	Peritoneal Cytology	.	RS	RS	RS	RS	.	.	NAACCR
3913	Pleural Effusion	.	RS	RS	RS	RS	.	.	NAACCR
3914	Progesterone Receptor Percent Positive or Range	.	RS	RS	RC	RC	.	.	NAACCR
3915	Progesterone Receptor Summary	RS	RS	RS	RS	RS	RS*	RS	NAACCR
3916	Progesterone Receptor Total Allred Score	.	RS	RS	.	RC	.	.	NAACCR	Revised
3917	Primary Sclerosing Cholangitis	.	RS	RS	.	RC	.	.	NAACCR
3918	Profound Immune Suppression	.	RS	RS	RS	RS	.	.	NAACCR
3919	EOD Prostate Pathologic Extension	.	.	.	RS	RS	.	.	SEER
3920	PSA (Prostatic Specific Antigen) Lab Value	RS	RS	RS	RS	RS	RS*	RS	NAACCR
3921	Residual Tumor Volume Post Cytoreduction	.	RS	RS	RS	RS	.	.	NAACCR
3922	Response to Neoadjuvant Therapy	.	RS	RS	RC	RC	.	.	NAACCR
3923	S Category Clinical	.	RS	RS	RS	RS	RS*	RS	NAACCR
3924	S Category Pathological	.	RS	RS	RS	RS	RS*	RS	NAACCR
3925	Sarcomatoid Features	.	RS	RS	RS	RS	.	.	NAACCR
3926	Schema Discriminator 1	RS	RS	RS	RS	RS	RS*	RS	NAACCR
3927	Schema Discriminator 2	RS	RS	RS	RS	RS	RS*	RS	NAACCR
3928	Schema Discriminator 3	.	RS	RS	RS	RS	RS*	RS	NAACCR
3929	Separate Tumor Nodules	.	RS	RS	RS	RS	.	.	NAACCR
3930	Serum Albumin Pretreatment Level	.	RS	RS	RS	RS	RS*	RS	NAACCR
3931	Serum Beta-2 Microglobulin Pretreatment Level	.	RS	RS	RS	RS	RS*	RS	NAACCR
3932	LDH Lab Value	RS	RS	RS	RS	RS	.	.	NAACCR
3933	Thrombocytopenia	.	RS	RS	RS	RS	RS*	RS	NAACCR
3934	Tumor Deposits	.	RS	RS	RS	RS	.	.	NAACCR
3935	Tumor Growth Pattern	.	RS	RS	.	RS	.	.	NAACCR
3936	Ulceration	.	RS	RS	RS	RS	RS*	RS	NAACCR
3937	Visceral and Parietal Pleural Invasion	.	RS	RS	RS	RS	.	.	NAACCR
3938	ALK Rearrangement	.	RS		R		.		NAACCR
3939	EGFR Mutational Analysis	.	RS		R		.		NAACCR
3940	BRAF Mutational Analysis	.	RS		R		.		NAACCR
3941	NRAS Mutational Analysis	.	RS		R		.		NAACCR
3942	CA 19-9 PreTX Lab Value	.	RS		R		.		NAACCR
3943	NCDB--SARSCoV2--Test	.	RH		RH*		.		CoC
3944	NCDB--SARSCoV2--Pos	.	RH		RH*		.		CoC
3945	NCDB--SARSCoV2--Pos Date	.	RH		RH*		.		CoC
3946	NCDB--COVID19--Tx Impact	.	RH		RH*		.		CoC
3950	Macroscopic Evaluation of Mesorectum	.	R		RC		.		CoC
3955	Derived Rai Stage	.	.		D		.
3956	p16	RS	RS		RS		RS*		SEER	Revised
3957	LN Status Pelvic	.	RS		RC		RS*		SEER
3958	LN Status Para-Aortic	.	RS		RC		RS*		SEER
3959	LN Status Femoral-Inguinal	.	RS		RC		RS*		SEER
3960	Histologic Subtype	RS*	RS		RS		RS*		SEER	New
3961	Clinical Margin Width	.	RS		RS		.		CoC	New
7010	Path Reporting Fac ID 1	.	.	.	.	.	.	.	HL7
7011	Path Reporting Fac ID 2	.	.	.	.	.	.	.	HL7
7012	Path Reporting Fac ID 3	.	.	.	.	.	.	.	HL7
7013	Path Reporting Fac ID 4	.	.	.	.	.	.	.	HL7
7014	Path Reporting Fac ID 5	.	.	.	.	.	.	.	HL7
7090	Path Report Number 1	.	.	.	.	.	.	.	HL7
7091	Path Report Number 2	.	.	.	.	.	.	.	HL7
7092	Path Report Number 3	.	.	.	.	.	.	.	HL7
7093	Path Report Number 4	.	.	.	.	.	.	.	HL7
7094	Path Report Number 5	.	.	.	.	.	.	.	HL7
7100	Path Order Phys Lic No 1	.	.	.	.	.	.	.	HL7
7101	Path Order Phys Lic No 2	.	.	.	.	.	.	.	HL7
7102	Path Order Phys Lic No 3	.	.	.	.	.	.	.	HL7
7103	Path Order Phys Lic No 4	.	.	.	.	.	.	.	HL7
7104	Path Order Phys Lic No 5	.	.	.	.	.	.	.	HL7
7190	Path Ordering Fac No 1	.	.	.	.	.	.	.	HL7
7191	Path Ordering Fac No 2	.	.	.	.	.	.	.	HL7
7192	Path Ordering Fac No 3	.	.	.	.	.	.	.	HL7
7193	Path Ordering Fac No 4	.	.	.	.	.	.	.	HL7
7194	Path Ordering Fac No 5	.	.	.	.	.	.	.	HL7
7320	Path Date Spec Collect 1	.	.	.	.	.	.	.	HL7
7321	Path Date Spec Collect 2	.	.	.	.	.	.	.	HL7
7322	Path Date Spec Collect 3	.	.	.	.	.	.	.	HL7
7323	Path Date Spec Collect 4	.	.	.	.	.	.	.	HL7
7324	Path Date Spec Collect 5	.	.	.	.	.	.	.	HL7
7480	Path Report Type 1	.	.	.	.	.	.	.	HL7
7481	Path Report Type 2	.	.	.	.	.	.	.	HL7
7482	Path Report Type 3	.	.	.	.	.	.	.	HL7
7483	Path Report Type 4	.	.	.	.	.	.	.	HL7
7484	Path Report Type 5	.	.	.	.	.	.	.	HL7